Huons BioPharma's HU-045 wrinkle remedy starts Phase 2 trials

Huons BioPharma logo [HUONS BIOPHARMA]

Huons BioPharma was granted permission to start Phase 2 clinical trials of its botulinum toxin candidate, the company said Tuesday.

With the approval from the Ministry of Food and Drug Safety, the trials will be conducted on adults who suffer moderate to severe frown lines to test its safety and efficacy. The candidate, HU-045, is formulated to reduce worry lines.

The fully-owned subsidiary of Huons Global said the candidate’s Phase 1 clinical trials produced meaningful results to prove its safety and tolerability. The company expects results from the Phase 2 clinical trials starting in 2023.

“Since we have proved enough efficacy and safety of HU-045 through Phase 1 trials, the Phase 2 clinical trials will likely be successful,” said Kim Yeong-mok, CEO of Huons BioPharma, said in Tuesday’s release. “HU-045 will become one of Huons’ major products and can become a leader in the global botulinum toxin market.”

BY SARAH CHEA [chea.sarah@joongang.co.kr]